References
- Kaiser family foundation. HIV Viral suppression rate in U.S. lowest among comparable high-income countries. Kaiser family foundation. 2021. https://www.kff.org/hivaids/slide/hiv-viral-suppression-rate-in-u-s-lowest-among-comparable-high-income-countries/. Accessed 4 Jan 2021.
- McCann NC, Horn TH, Hyle EP, Walensky RPHIV antiretroviral therapy costs in the United States, 2012–2018JAMA Intern Med20201804601603 10.1001/jamainternmed.2019.7108 32011622 7042880
- Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BPEnding the HIV epidemic: a plan for the United StatesJAMA20193219844845 10.1001/jama.2019.1343 30730529
- Office of Infectious Disease and HIV/AIDS Policy, U.S. Department of Health & Human Services. Priority Jurisdictions: Phase I. HIV.gov. 2020. https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/jurisdictions/phase-one. Accessed 14 Feb 2021.
- Zamani-Hank YThe affordable care act and the burden of high cost sharing and utilization management restrictions on access to HIV medications for people living with HIV/AIDSPopul Health Manag2015194272278 10.1089/pop.2015.0076 26565514
- Dawson L, Kates J. Insurance coverage and viral suppression among people with HIV, 2018. Kaiser Family Foundation; 2020. https://www.kff.org/hivaids/issue-brief/insurance-coverage-and-viral-suppression-among-people-with-hiv-2018/. Accessed 14 Feb 2021.
- Kates J, Dawson L. Insurance coverage changes for people with HIV under the ACA. Kaiser Family Foundation; 2017. https://www.kff.org/health-reform/issue-brief/insurance-coverage-changes-for-people-with-hiv-under-the-aca/. Accessed 14 Feb 2021.
- Dawson L, Kates J. The Ryan white program and insurance purchasing in the ACA Era: an early look at five states. Kaiser family foundation. 2015. https://www.kff.org/report-section/the-ryan-white-program-and-insurance-purchasing-in-the-aca-era-background/. Accessed 21 Oct 2021.
- Health resources and services administration (HRSA). AIDS drug assistance program (ADAP) annual client-level data report—2018. Ryan white HIV/AIDS program (RWHAP); 2020. https://hab.hrsa.gov/sites/default/files/hab/data/datareports/2018-hrsa-adr-data-report.pdf Accessed 21 Oct 2021.
- McManus KA, Rodney RC, Rhodes A, Bailey S, Dillingham RAffordable care act qualified health plan enrollment for AIDS drug assistance program clients: Virginia’s experience and best practicesAIDS Res Hum Retroviruses2016329885891 10.1089/AID.2016.0033 27346694 5028904
- Furl R, Watanabe-Galloway S, Lyden E, Swindells SDeterminants of facilitated health insurance enrollment for patients with HIV disease, and impact of insurance enrollment on targeted health outcomesBMC Infect Dis.2018 10.1186/s12879-018-3035-7 29548324 5857141
- McManus KA, Rhodes A, Yerkes L, Engelhard CL, Ingersoll KS, Dillingham RYear 2 of affordable care act qualified health plans (QHPs) in a medicaid nonexpansion state: QHPs associated with viral suppression for Virginia AIDS drug assistance program clientsOpen Forum Infect Dis.2018512ofy283 10.1093/ofid/ofy283 30568977 6293482
- McManus KA, Rhodes A, Bailey S, et al.Affordable care act qualified health plan coverage: association with improved hiv viral suppression for AIDS drug assistance program clients in a medicaid nonexpansion stateClin Infect Dis2016633396403 10.1093/cid/ciw277 27143661 4946015
- McManus KA, Christensen B, Nagraj VP, et al.Evidence from a multistate cohort: enrollment in affordable care act qualified health plans’ association with viral suppressionClin Infect Dis2020711025722580 10.1093/cid/ciz1123 31734691
- Centers for medicare and medicaid services. Information on essential health benefits (EHB) benchmark plans. CMS.gov. 2022. https://www.cms.gov/CCIIO/Resources/Data-Resources/ehb. Accessed 21 Feb 2022.
- Shepherd JPharmacy benefit managers, rebates, and drug prices: conflicts of interest in the market for prescription drugsYale Law Policy Rev201938360
- Sood N, Shih T, Van Nuys K, Goldman D. The flow of money through the pharmaceutical distribution system. Schaeffer Center for Health Policy and Economics. 2017. https://pharmaceutical.report/Resources/Whitepapers/4d3550b8-f007-4bef-9770-83b338b5a704_USC%20Schaeffer_Flow%20of%20Money_2017.pdf.
- Dickson S. Discriminatory Design: HIV Treatment in the Marketplace. National Alliance of State and Territorial AIDS Directors (NASTAD); 2016. https://www.nastad.org/sites/default/files/Discriminatory-Design-HIV-Treatment-in-the-Marketplace.pdf. Accessed 4 Jan 2021.
- McMenamin SB, Shimkhada R, Hiller SP, Corbett G, Ponce NAddressing discriminatory benefit design for people living with HIV: a California case studyAIDS Care2017291215941597 10.1080/09540121.2017.1313385 28393587
- Jacobs DB, Sommers BDUsing drugs to discriminate — adverse selection in the insurance marketplaceN Engl J Med2015372399402 1:CAS:528:DC%2BC2MXhtVOgsrjK 10.1056/NEJMp1411376 25629737
- McManus KA, Powers S, Killelea A, Tello-Trillo S, McQuade Rogawski ERegional disparities in qualified health plans’ prior authorization requirements for HIV pre-exposure prophylaxis in the United StatesJAMA Netw Open.202036 10.1001/jamanetworkopen.2020.7445 32492164 7272119
- Raifman J, Althoff K, Rebeiro PF, et al.Human immunodeficiency virus (HIV) viral suppression after transition from having no healthcare coverage and relying on Ryan white HIV/AIDS program support to medicaid or private health insuranceClin Infect Dis2019693538541 10.1093/cid/ciy1088 30590421
- Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. U.S. Department of health and human services; 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed 5 Jan 2021.
- Saag MS, Gandhi RT, Hoy JF, et al.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society–USA panelJAMA2020324161651 1:CAS:528:DC%2BB3cXit1WiurbM 10.1001/jama.2020.17025 33052386
- Acosta RK, Willkom M, Martin R, et al.Resistance analysis of Bictegravir–Emtricitabine–Tenofovir Alafenamide in HIV-1 treatment-naive patients through 48 weeksAntimicrob Agents Chemother.2019635e0253318 1:CAS:528:DC%2BC1MXhtFeiur%2FP 10.1128/AAC.02533-18 30803969 6496090
- Coffey S, Bacchetti P, Sachdev D, et al.RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic populationAIDS2019335825832 1:CAS:528:DC%2BC1MXltVegt7w%3D 10.1097/QAD.0000000000002124 30882490
- Akinwunmi B, Buchenberger D, Scherzer J, et al.Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western EuropeEur J Pub Health2021313567575 10.1093/eurpub/ckaa229
- Parraga Acosta T, Osborn Z, Lee JC, Haubrich RH, McNicholl I, McKinnon JEPilot comparison of the ease of swallowing of single tablet antiretroviral regimensAIDS Care2021 10.1080/09540121.2021.1939258 34125632
- U.S. centers for medicare and medicaid services. National average drug acquisition cost. Data.Medicaid.gov. 2022. https://data.medicaid.gov/nadac. Accessed 12 Mar 2022.
- INSIGHT START Study GroupLundgren JD, Babiker AG, et al.Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionN Engl J Med.20153739795807 1:CAS:528:DC%2BC28XkvFGjsA%3D%3D 10.1056/NEJMoa1506816
- Koenig SP, Dorvil N, Dévieux JG, et al.Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trialPLoS Med.2017147 10.1371/journal.pmed.1002357 28742880 5526526
- Pilcher CD, Ospina-Norvell C, Dasgupta A, et al.The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health settingJ Acquir Immune Defic Syndr20177414451 1:CAS:528:DC%2BC28XitVGrtbjP 10.1097/QAI.0000000000001134 27434707 5140684
- Labhardt ND, Ringera I, Lejone TI, et al.Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trialJAMA20183191111031112 10.1001/jama.2018.1818 29509839 5885884
- Mateo-Urdiales A, Johnson S, Smith R, Nachega JB, Eshun-Wilson IRapid initiation of antiretroviral therapy for people living with HIVCochrane Database Syst Rev.20196CD012962 10.1002/14651858.CD012962.pub2 31206168
- Colasanti J, Sumitani J, Mehta CC, et al.Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United StatesOpen Forum Infect Dis.201856ofy104 10.1093/ofid/ofy104 29992172 6022569
- Alexander GC, Ballreich J, Socal MP, et al.Reducing branded prescription drug prices: a review of policy optionsPharmacotherapy2017371114691478 10.1002/phar.2013 28805961
- Beer L, Tie Y, Weiser J, Shouse RLNonadherence to any prescribed medication due to costs among adults with HIV infection—United States, 2016–2017MMWR Morb Mortal Wkly Rep2019684911291133 10.15585/mmwr.mm6849a1 31830009 6919290
- Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas VEconomic impact of medication non-adherence by disease groups: a systematic reviewBMJ Open.201881 10.1136/bmjopen-2017-016982 29358417 5780689
- Panel on antiretroviral guidelines for adults and adolescents. Cost considerations and antiretroviral therapy. U.S. Department of health and human services. 2021. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/cost-considerations-and-antiretroviral-therapy. Accessed 15 Dec 2021.
- U.S. Department of health and human services. HIV treatment as prevention. HIV.gov. 2020. https://www.hiv.gov/tasp. Accessed 4 July 2021.
- Sansom SL, Hicks KA, Carrico J, et al.Optimal allocation of societal HIV prevention resources to reduce hiv incidence in the United StatesAm J Public Health20211111150158 10.2105/AJPH.2020.305965 33211582 7750609
- Swindells S, Andrade-Villanueva JF, Richmond GJ, et al.Long-acting Cabotegravir and Rilpivirine for maintenance of HIV-1 suppressionN Engl J Med2020 10.1056/NEJMoa1904398 32130809
- Orkin C, Arasteh K, Hernández-Mora MG, et al.Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionN Engl J Med2020 10.1056/NEJMoa1909512 32130806
- U.S. food and drug administration. FDA Approves first extended-release, injectable drug regimen for adults living with HIV. 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv. Accessed 22 Oct 2021.
- Ross EL, Weinstein MC, Schackman BR, et al.The clinical role and cost-effectiveness of long-acting antiretroviral therapyClin Infect Dis201560711021110 10.1093/cid/ciu1159 25583979 4366583
- Scarsi KK, Swindells SThe promise of improved adherence with long-acting antiretroviral therapy: what are the data?J Int Assoc Provid AIDS Care20212023259582211009012 10.1177/23259582211009011
- National alliance of state and territorial AIDS directors (NASTAD), HIV medicine association (HIVMA), American academy of HIV medicine (AAHIVM). Preparing for long-acting antiretroviral treatment. 2021. https://aahivm.org/wp-content/uploads/2021/03/Long-Acting-ARVs-_Final-2-25-21_PDF.pdf. Accessed 22 Oct 2021.
- Adekunle D. Can long-acting ART be an equitable care option for black women? The Body. 2021. https://www.thebody.com/article/long-acting-antiretroviral-therapy-for-black-women. Accessed 22 Oct 2021.
- Essien UR, Dusetzina SB, Gellad WFA policy prescription for reducing health disparities—achieving pharmacoequityJAMA2021 10.1001/jama.2021.17764 34677579
- Entis L. Why does medicine cost so much? Here’s how drug prices are set. Time. 2019. https://time.com/5564547/drug-prices-medicine/. Accessed 22 Oct 2021.
- Waxman H, Corr B, Sharp J, McDonald R, Kenyatta KGetting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address themCommonwealth Fund2020 10.26099/dys3-en63
- McManus KA, Engelhard CL, Dillingham RCurrent challenges to the United States’ AIDS drug assistance program and possible implications of the affordable care actAIDS Res Treat20132013 10.1155/2013/350169